![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
NVIDIA
NVDA
Tesla
TSLA
Super Micro Computer
SMCI
4
Palantir
PLTR
5
Hims & Hers Health
HIMS
US Stock MarketDetailed Quotes
INKT MiNK Therapeutics
- 9.660
- -0.990-9.30%
Close Feb 25 16:00 ET
- 9.660
- 0.0000.00%
Post 20:01 ET
38.28MMarket Cap-2.61P/E (TTM)
10.736High9.090Low24.58KVolume10.320Open10.650Pre Close235.35KTurnover2.42%Turnover RatioLossP/E (Static)3.96MShares19.00052wk High-2.18P/B9.81MFloat Cap4.56052wk Low--Dividend TTM1.02MShs Float221.550Historical High--Div YieldTTM15.45%Amplitude4.560Historical Low9.573Avg Price1Lot Size
MiNK Therapeutics Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (pres...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (pres...
63
7
4
$AtlasClear (ATCH.US)$ 2.68 -13.189 =392% MEGA RUNNER
$CN Energy (CNEY.US)$ 0.2919-0.4512 = 54.57% RUNNER
$Cheetah Net Supply Chain Service (CTNT.US)$ 1.96-2.37 = 20.92%
$Golden Sun Health Technology (GSUN.US)$ 2.35-5.25 = 123% MEGA RUNNER
$MicroCloud Hologram (HOLO.US)$ 1.508 - 1.94 = 28.65%
$MiNK Therapeutics (INKT.US)$ 9.99-12 = 20.12%
$iSpecimen (ISPC.US)$ 2.06-3.03...
$CN Energy (CNEY.US)$ 0.2919-0.4512 = 54.57% RUNNER
$Cheetah Net Supply Chain Service (CTNT.US)$ 1.96-2.37 = 20.92%
$Golden Sun Health Technology (GSUN.US)$ 2.35-5.25 = 123% MEGA RUNNER
$MicroCloud Hologram (HOLO.US)$ 1.508 - 1.94 = 28.65%
$MiNK Therapeutics (INKT.US)$ 9.99-12 = 20.12%
$iSpecimen (ISPC.US)$ 2.06-3.03...
44
35
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press rele...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press rele...
77
17
10
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
71
23
3
$MiNK Therapeutics (INKT.US)$ Reuters· 1 min ago
Mink Therapeutics Regains Full Compliance With Nasdaq Listing Requirements
Mink Therapeutics Regains Full Compliance With Nasdaq Listing Requirements
$MiNK Therapeutics (INKT.US)$
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
Thursday, 20th February at 7:30 am
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, today announced that it has received formal ...
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
Thursday, 20th February at 7:30 am
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, today announced that it has received formal ...
1
$MiNK Therapeutics (INKT.US)$
Groundbreaking Gastric Cancer Trial Results: MiNK's Triple Therapy Approach Takes Center Stage at AACR
Groundbreaking Gastric Cancer Trial Results: MiNK's Triple Therapy Approach Takes Center Stage at AACR
$MiNK Therapeutics (INKT.US)$
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
Wednesday, 12th February at 1:00 pm
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated...
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
Wednesday, 12th February at 1:00 pm
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated...
1
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you ...
63
25
9
$MiNK Therapeutics (INKT.US)$
MiNK Therapeutics Advances Novel Cancer Therapy with Promising Phase 2 Trial at Memorial Sloan Kettering
MiNK Therapeutics Advances Novel Cancer Therapy with Promising Phase 2 Trial at Memorial Sloan Kettering
2
No comment yet
Fox45 : Thanks, Jag!
151482685 : thank you fir shsring your insights … much appreciated alm your effort![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Edward PaperHands : are you watching for a reversal for HMR or are you watching for more collapse
SR Lee MYR : really appreciated Jag
Huaw : I do not understand why HMR only had a total of 28.37 million shares yesterday.
Today, it has become a total of 56.75 million shares.
It's almost doubled, and the Market Cap has also doubled.
Why is this happening?
View more comments...